RA Kyle et al.: Review of 1027 patients with newly diagnosed multiple myeloma. In: Mayo Clin Proc. 78. Jahrgang, Nr.1, Januar 2003, S.21–33, doi:10.4065/78.1.21, PMID 12528874.
A Dispenzieri et al.: Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. In: Lancet. 375. Jahrgang, Nr.9727, 15. Mai 2010, S.1721–1728, doi:10.1016/S0140-6736(10)60482-5, PMID 20472173.
RA Kyle et al.: Prevalence of monoclonal gammopathy of undetermined significance. In: N Engl J Med. 354. Jahrgang, Nr.13, 30. März 2006, S.1362–1369, doi:10.1056/NEJMoa054494, PMID 16571879.
N van de Donk et al.: The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. In: Haematologica. 99. Jahrgang, Nr.6, 21. März 2014, S.984–96, doi:10.3324/haematol.2013.100552, PMID 23224402, PMC 4040895 (freier Volltext).
A Dispenzieri et al.: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. In: Leukemia. 23. Jahrgang, Nr.2, 20. November 2008, S.215–224, doi:10.1038/leu.2008.307, PMID 19020545.
SV Rajkumar et al.: International Myeloma Working Group updated criteria for
the diagnosis of multiple myeloma. In: Lancet Oncology. 15. Jahrgang, November 2014, S.e538–e548, doi:10.1038/leu.2010.60, PMID 20410922.
RA Kyle et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. In: N Engl J Med. 346. Jahrgang, Nr.8, 21. Februar 2002, S.564–569, doi:10.1056/NEJMoa01133202, PMID 11856795.
C Cesana et al.: Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. In: J Clin Oncol. 20. Jahrgang, Nr.6, 15. März 2002, S.1625–1634, doi:10.1200/JCO.2002.20.6.1625, PMID 11896113.
J Bladé et al.: Pathogenesis and progression of monoclonal gammopathy of undetermined significance. In: Leukemia. 22. Jahrgang, Nr.9, 26. März 2008, S.1651–7, doi:10.1038/leu.2008.203, PMID 18668131.
RA Kyle et al.: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma:IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. In: Leukemia. 24. Jahrgang, 4. Februar 2010, S.1121–1127, doi:10.1038/leu.2010.60, PMID 20410922.
N Leung et al.: Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. In: Blood. 120. Jahrgang, Nr.22, 22. November 2012, S.4292–4295, doi:10.1182/blood-2012-07-445304, PMID 23224402.
JP Fermand et al.: How I treat monoclonal gammopathy of renal significance (MGRS). In: Blood. 122. Jahrgang, Nr.22, 9. Oktober 2013, S.3583–3590, doi:10.1182/blood-2013-05-495929, PMID 24108460.
nih.gov
ncbi.nlm.nih.gov
RA Kyle et al.: Review of 1027 patients with newly diagnosed multiple myeloma. In: Mayo Clin Proc. 78. Jahrgang, Nr.1, Januar 2003, S.21–33, doi:10.4065/78.1.21, PMID 12528874.
A Dispenzieri et al.: Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. In: Lancet. 375. Jahrgang, Nr.9727, 15. Mai 2010, S.1721–1728, doi:10.1016/S0140-6736(10)60482-5, PMID 20472173.
RA Kyle et al.: Prevalence of monoclonal gammopathy of undetermined significance. In: N Engl J Med. 354. Jahrgang, Nr.13, 30. März 2006, S.1362–1369, doi:10.1056/NEJMoa054494, PMID 16571879.
N van de Donk et al.: The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. In: Haematologica. 99. Jahrgang, Nr.6, 21. März 2014, S.984–96, doi:10.3324/haematol.2013.100552, PMID 23224402, PMC 4040895 (freier Volltext).
A Dispenzieri et al.: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. In: Leukemia. 23. Jahrgang, Nr.2, 20. November 2008, S.215–224, doi:10.1038/leu.2008.307, PMID 19020545.
SV Rajkumar et al.: International Myeloma Working Group updated criteria for
the diagnosis of multiple myeloma. In: Lancet Oncology. 15. Jahrgang, November 2014, S.e538–e548, doi:10.1038/leu.2010.60, PMID 20410922.
RA Kyle et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. In: N Engl J Med. 346. Jahrgang, Nr.8, 21. Februar 2002, S.564–569, doi:10.1056/NEJMoa01133202, PMID 11856795.
C Cesana et al.: Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. In: J Clin Oncol. 20. Jahrgang, Nr.6, 15. März 2002, S.1625–1634, doi:10.1200/JCO.2002.20.6.1625, PMID 11896113.
J Bladé et al.: Pathogenesis and progression of monoclonal gammopathy of undetermined significance. In: Leukemia. 22. Jahrgang, Nr.9, 26. März 2008, S.1651–7, doi:10.1038/leu.2008.203, PMID 18668131.
RA Kyle et al.: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma:IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. In: Leukemia. 24. Jahrgang, 4. Februar 2010, S.1121–1127, doi:10.1038/leu.2010.60, PMID 20410922.
N Leung et al.: Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. In: Blood. 120. Jahrgang, Nr.22, 22. November 2012, S.4292–4295, doi:10.1182/blood-2012-07-445304, PMID 23224402.
JP Fermand et al.: How I treat monoclonal gammopathy of renal significance (MGRS). In: Blood. 122. Jahrgang, Nr.22, 9. Oktober 2013, S.3583–3590, doi:10.1182/blood-2013-05-495929, PMID 24108460.
